Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy.

MLA

Nauffal, Victor, et al. “Worldwide Differences in Primary Prevention Implantable Cardioverter Defibrillator Utilization and Outcomes in Hypertrophic Cardiomyopathy.” European Heart Journal, vol. 42, no. 38, Oct. 2021, pp. 3932–44. EBSCOhost, https://doi.org/10.1093/eurheartj/ehab598.

APA

Nauffal, V., Marstrand, P., Han, L., Parikh, V. N., Helms, A. S., Ingles, J., Jacoby, D., Lakdawala, N. K., Kapur, S., Michels, M., Owens, A. T., Ashley, E. A., Pereira, A. C., Rossano, J. W., Saberi, S., Semsarian, C., Ware, J. S., Wittekind, S. G., Day, S., & Olivotto, I. (2021). Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. European Heart Journal, 42(38), 3932–3944. https://doi.org/10.1093/eurheartj/ehab598

Chicago

Nauffal, Victor, Peter Marstrand, Larry Han, Victoria N Parikh, Adam S Helms, Jodie Ingles, Daniel Jacoby, et al. 2021. “Worldwide Differences in Primary Prevention Implantable Cardioverter Defibrillator Utilization and Outcomes in Hypertrophic Cardiomyopathy.” European Heart Journal 42 (38): 3932–44. doi:10.1093/eurheartj/ehab598.